MX2014005196A - Modelo de citotoxidad celular dependiente de anticuerpos (adcc) in vivo. - Google Patents

Modelo de citotoxidad celular dependiente de anticuerpos (adcc) in vivo.

Info

Publication number
MX2014005196A
MX2014005196A MX2014005196A MX2014005196A MX2014005196A MX 2014005196 A MX2014005196 A MX 2014005196A MX 2014005196 A MX2014005196 A MX 2014005196A MX 2014005196 A MX2014005196 A MX 2014005196A MX 2014005196 A MX2014005196 A MX 2014005196A
Authority
MX
Mexico
Prior art keywords
model
vivo adcc
antibodies
determining
vivo
Prior art date
Application number
MX2014005196A
Other languages
English (en)
Inventor
Pablo Umana
Daniel Breustedt
Christian Gerdes
Antonio Iglesias
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of MX2014005196A publication Critical patent/MX2014005196A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)

Abstract

La presente invención se relaciona con un animal no humano que comprende un locus de FcgR de baja afinidad, humanizado. También se proporciona en la presente el uso de tal animal no humano para determinar la eficacia in vivo de los anticuerpos, y con métodos para determinar la eficacia in vivo de los anticuerpos.
MX2014005196A 2011-11-01 2012-10-29 Modelo de citotoxidad celular dependiente de anticuerpos (adcc) in vivo. MX2014005196A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11187392 2011-11-01
PCT/EP2012/071328 WO2013064443A1 (en) 2011-11-01 2012-10-29 In vivo adcc model

Publications (1)

Publication Number Publication Date
MX2014005196A true MX2014005196A (es) 2014-05-28

Family

ID=47088881

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005196A MX2014005196A (es) 2011-11-01 2012-10-29 Modelo de citotoxidad celular dependiente de anticuerpos (adcc) in vivo.

Country Status (11)

Country Link
US (1) US20160058891A1 (es)
EP (1) EP2773766A1 (es)
JP (1) JP2014532399A (es)
KR (1) KR20140089521A (es)
CN (1) CN103906842A (es)
BR (1) BR112014007946A2 (es)
CA (1) CA2849866A1 (es)
HK (1) HK1199288A1 (es)
MX (1) MX2014005196A (es)
RU (1) RU2014120375A (es)
WO (1) WO2013064443A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6267986B2 (ja) * 2014-02-13 2018-01-24 株式会社特殊免疫研究所 ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法
KR20210116480A (ko) 2019-01-17 2021-09-27 리제너론 파마슈티칼스 인코포레이티드 기분 장애의 설치류 모델

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877396A (en) * 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
US6676927B1 (en) * 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies
KR101666229B1 (ko) * 2008-02-08 2016-10-14 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
SI2516457T1 (en) * 2009-12-21 2018-08-31 Regeneron Pharmaceuticals, Inc. MUSHROOM WITH HUMANIZED FC GAMES R

Also Published As

Publication number Publication date
JP2014532399A (ja) 2014-12-08
CA2849866A1 (en) 2013-05-10
EP2773766A1 (en) 2014-09-10
HK1199288A1 (en) 2015-06-26
WO2013064443A1 (en) 2013-05-10
BR112014007946A2 (pt) 2017-04-11
RU2014120375A (ru) 2015-12-10
US20160058891A1 (en) 2016-03-03
KR20140089521A (ko) 2014-07-15
CN103906842A (zh) 2014-07-02

Similar Documents

Publication Publication Date Title
PH12014501108A1 (en) Anti-il-36r antibodies
HK1185100A1 (zh) 用於生產帶有人抗體可變區的可繁殖轉殖基因動物
MX2015017487A (es) Anticuerpos cd3 humanizados o quimericos.
HK1202804A1 (en) Treatment with anti-pcsk9 antibodies pcsk9
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
EA201201357A1 (ru) Антитела к cd40
WO2013063391A3 (en) Transgenic animals and methods of use
IL232219B (en) Human or humanized antibodies against tar-dna-binding protein 43kda and their uses
IL228802A0 (en) Bispecific antibodies against 2her and 3cd
ZA201401267B (en) Antibodies to pcsk9 and uses thereof
EP2748199A4 (en) ANTI-OX40 ANTIBODIES AND METHOD FOR THEIR USE
MX2013005015A (es) Anticuerpos anti-il-23.
PH12014502406B1 (en) Anti-il-23p19 antibodies
EP2771694A4 (en) MONOCLONAL ANTIBODIES AND METHOD FOR THEIR USE
HK1199837A1 (en) Humanized antibodies to inkt inkt
PL2542575T3 (pl) Ekspresja przeciwciał monoklonalnych u tetrahymena
EP2841453A4 (en) HUMANIZED AND CHIMERIC C3 ANTI-FACTOR ANTIBODIES AND USES THEREOF
WO2012149412A3 (en) Anti-endoglin (cd105) antibodies, immunoconjugates, and uses thereof
GB201109238D0 (en) Antibodies
HK1198367A1 (en) Method of treating alveolar bone loss through the use of anti- sclerostin antibodies
HK1207870A1 (en) Anti-human sema4a antibodies useful to treat disease sema4a
MX2016005854A (es) Anticuerpo anti-her3 alosterico de la neuregulina.
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.
SG10201708562VA (en) IL-1β Neutralizing Human Monoclonal Antibodies
MX2014005196A (es) Modelo de citotoxidad celular dependiente de anticuerpos (adcc) in vivo.